Quarterly ResultMay 13, 2026, 04:09 PM
Adicet Bio Q1 Net Loss $20.2M; Prula-cel Data Mid-2026
AI Summary
Adicet Bio reported a net loss of $20.2 million for the first quarter ended March 31, 2026, an improvement from $28.2 million in the same period last year, with R&D expenses decreasing to $17.5 million. The company holds $137.6 million in cash, cash equivalents, and short-term investments, projecting a cash runway into the second half of 2027. Operationally, Adicet Bio anticipates a Phase 1 clinical update for prula-cel in autoimmune diseases in mid-2026 and expects FDA interaction on pivotal trial design in Q2 2026. Additionally, a regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer is planned for Q3 2026, with Phase 1 enrollment expected in Q4 2026.
Key Highlights
- Net loss for Q1 2026 was $20.2 million, an improvement from $28.2 million in Q1 2025.
- Research and Development expenses decreased to $17.5 million in Q1 2026 from $22.8 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $137.6 million as of March 31, 2026.
- The company expects its cash runway to fund operating expenses into the second half of 2027.
- A Phase 1 clinical update for prula-cel in at least 20 LN and SLE patients is anticipated in mid-2026.
- FDA interaction regarding potential pivotal trial design for prula-cel is expected in Q2 2026.
- Regulatory submission for ADI-212 in mCRPC is planned for Q3 2026.
- Phase 1 enrollment for ADI-212 is anticipated in Q4 2026, pending regulatory clearance.